Navigation Links
Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
Date:9/3/2009

AURORA, Ontario, Sept. 3 /PRNewswire/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: "HXBPF") today announced that John Docherty, president and chief operating officer, will present at the Rodman and Renshaw 11th Annual Healthcare Conference at 12:05 p.m. EDT on Wednesday, Sept. 9, at the New York Palace Hotel in New York. Mr. Docherty will provide an overview of the Company's leading product development programs L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company's website, www.helixbiopharma.com, on September 9th, 2009.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is listed on the TSX and FSE under the symbol "HBP" and on the OTCQX International Market under the symbol "HXBPF".

For further information contact:

    Investor & Media Relations
    Robert Flamm, Ph.D.                        Ian Stone
    Russo Partners LLC                         Russo Partners LLC
    Tel: (212) 845-4226                        Tel: (619) 814-3510
    Email: robert.flamm@russopartnersllc.com   Fax: (619) 955-5318
    www.russopartnersllc.com                   Email:
                                               ian.stone@russopartnersllc.com

This News Release contains certain forward-looking statemen
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses
2. New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix
3. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
4. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
5. Helix BioPharma to Present at the BioFinance 2009 Conference
6. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
7. Helix BioPharma Announces Q2 2009 Financial Results
8. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
9. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
10. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
11. Helix BioPharma Announces Q1 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... India , September 3, 2015 ... Instruments Market by System (LC (HPLC, UHPLC, Flash), GC, ... Phase Columns, Syringe Filters, Vials) - Analysis & Global ... Market is expected to reach around 9.223 Billion by ... CAGR of 5.5%. Browse 141 tables and ...
(Date:9/2/2015)... 2015 Research and Markets ( ... Jain PharmaBiotech,s new report "Nanobiotechnology Applications, ... An increasing use of ... is anticipated. Nanotechnology will be applied at ... formulations for optimal delivery to diagnostic applications ...
(Date:9/2/2015)... Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report ... their offering. This report follows the ... that can be objectively measured and evaluated as ... as well as pharmacological responses to a therapeutic ...
(Date:9/2/2015)... Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., announced ... the multicenter Phase 2 clinical trial of NT-503 ... of recurrent subfoveal choroidal neovascularization secondary to age ... unique vascular endothelial growth factor (VEGF) receptor protein ... "This landmark proof-of-concept study will evaluate NT-503 ...
Breaking Biology Technology:Chromatography Instruments Market Worth $ 9.223 Billion by 2020 2Chromatography Instruments Market Worth $ 9.223 Billion by 2020 3Chromatography Instruments Market Worth $ 9.223 Billion by 2020 4Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4
... Point of Preventing Bacterial Colonization with ... Leader, VANCOUVER, March 18 /PRNewswire-FirstCall/ - ... ANP), a global specialty pharmaceutical and,medical device ... from its 960,patient clinical trial comparing its ...
... RainDance Technologies, Inc.,a developer of NanoReactor ... Stephen E. Becker as Vice President,Commercial Officer, ... responsible for continuing the growth of the,company,s ... launch of its first,life science offering," said ...
... AAAAI 64th Annual Meeting also show that C1-INH is ... HAE attacks across all body sites, PHILADELPHIA, March ... effective therapy that rapidly relieves acute,abdominal and facial swelling ... serious genetic disorder, according to data,presented today at the ...
Cached Biology Technology:960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 2960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 3960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 4960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 5960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 6960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 7RainDance Appoints Becker Chief Commercial Officer 2RainDance Appoints Becker Chief Commercial Officer 3C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 2C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 3C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 4
(Date:8/5/2015)... ALBANY, New York , August 5, 2015 /PRNewswire/ ... new market report titled "Facial Recognition Market - Global ... - 2022", the global market for facial recognition is ... market is driven by increased demand for surveillance systems ... to the rising number of crimes and terrorist activities ...
(Date:8/4/2015)... -- AMRI (NASDAQ: AMRI ) today reported financial and operating results ... , Second quarter contract revenue of $ 85.2 ... Adjusted contract margins of 26 % , ... decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, with ...
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... redundant portions of the fruit fly genome may not ... from a Princeton-led team of researchers suggest that repeated ... normal development under less-than-ideal growth conditions by making sure ... appropriate times. If similar regions are found in humans, ...
... estimated to afflict as many as 12 million people worldwide ... vulnerable to compounds developed to treat cancer and other disorders, ... have found. Scientists searched the genome of the parasite ... of TOR kinases, proteins that are linked to cell growth ...
... SPOKANE, Wash.Washington State University researchers have discovered a way to ... for slowing and even stopping the growth of tumors. "Hopefully, ... Weihang Chai, an assistant professor in the WSU School of ... "Basically, you make the cancer cell go from immortal to ...
Cached Biology News:Redundant genetic instructions in 'junk DNA' support healthy development 2Redundant genetic instructions in 'junk DNA' support healthy development 3Redundant genetic instructions in 'junk DNA' support healthy development 4Cancer drugs may help stop major parasite 2
Rat Hepatocytes (RH) (>3,000,000 cells)...
... a concentrated formulation of a rinsing buffer ... technology, as well as for manual immunostaining. ... Brigati M.D., Department of Pathology, University of ... recommended for all the rinsing steps performed ...
... Intended for users requiring mass ... AXIMA-LNR linear MALDI TOF Mass spectrometer ... QA/QC applications and for high performance ... oligonucleotide QA/QC, SNP analysis, protein detection, ...
Rat Dermal Fibroblasts (RDF) (>500,000 cells)...
Biology Products: